The pharma and life sciences industry currently globally pegged at US$874 billion is expected to reach US$1.22 trillion by 2022. The key drivers for growth are increasing life style diseases, such as cardiac disorders, diabetes, cancer etc., increase focus on personalized medicine, better understanding of human genome and its relationship with disease and tremendous technology development in healthcare. However in view of rising healthcare costs, the sector is facing challenges like increased regulatory oversight, decreased R&D productivity, growth and profitability challenges, and big data generation. These challenges are forcing pharma and life sciences companies to rework their strategies by leveraging extensive analytics and business intelligence tools.
course | Regular Classroom Program Advanced Post Graduate Diploma in Pharmaceutical Business Analytics |
duration | 6 months |
targeted exam | no |
fees | 75000 |